ADAMTS8

Chr 11

ADAM metallopeptidase with thrombospondin type 1 motif 8

Also known as: ADAM-TS8, METH2

The protein functions as a metalloproteinase with anti-angiogenic properties, disrupting blood vessel formation. Mutations in this gene have been associated with cancer predisposition, particularly lung neoplasms, following an autosomal dominant inheritance pattern. The gene shows minimal constraint against loss-of-function variants, suggesting some tolerance to protein disruption.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
9
Pubs (1 yr)
81
P/LP submissions
0%
P/LP missense
0.91
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryADAMTS8
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
81 unique Pathogenic / Likely Pathogenic· 158 VUS of 253 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.91LOEUF
pLI 0.000
Z-score 1.97
OE 0.63 (0.450.91)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.52Z-score
OE missense 0.93 (0.871.01)
469 obs / 501.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.63 (0.450.91)
00.351.4
Missense OE0.93 (0.871.01)
00.61.4
Synonymous OE1.03
01.21.6
LoF obs/exp: 21 / 33.3Missense obs/exp: 469 / 501.7Syn Z: -0.31
DN
0.6649th %ile
GOF
0.6542th %ile
LOF
0.2971th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

253 submitted variants in ClinVar

Classification Summary

Pathogenic74
Likely Pathogenic7
VUS158
Likely Benign6
74
Pathogenic
7
Likely Pathogenic
158
VUS
6
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
74
0
74
Likely Pathogenic
0
0
7
0
7
VUS
0
155
3
0
158
Likely Benign
0
5
0
1
6
Benign
0
0
0
0
0
Total0160841245

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ADAMTS8 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →